Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial

BACKGROUND: Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C-IVIG) is an unexplored therapy amidst the rapidly evolving spectrum of medical therapies for COVID-19 and is expected to counter the three most life-threatening consequences of COVID-19 including lung injury by the virus, cytokine s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:EClinicalMedicine
Autors principals: Ali, Shaukat, Uddin, Syed Muneeb, Shalim, Elisha, Sayeed, Muneeba Ahsan, Anjum, Fatima, Saleem, Farah, Muhaymin, Sheikh Muhammad, Ali, Ayesha, Ali, Mir Rashid, Ahmed, Iqra, Mushtaq, Tehreem, Khan, Sadaf, Shahab, Faisal, Luxmi, Shobha, Kumar, Suneel, Arain, Habiba, Khan, Mujtaba, Khan, Abdul Samad, Mehmood, Hamid, Rasheed, Abdur, Jahangeer, Ashraf, Baig, SaifUllah, Quraishy, Saeed
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177439/
https://ncbi.nlm.nih.gov/pubmed/34109306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100926
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars